Key result
Parasympathetic and sympathetic monitoring shows ~90% concordance with sudomotor testing for autonomic neuropathy.
Why the study?
The progression from peripheral autonomic neuropathy to cardiovascular autonomic neuropathy increases morbidity and mortality, and early detection methods need evaluation.
Does parasympathetic and sympathetic monitoring correlate with sudomotor testing in identifying early signs of autonomic neuropathy in patients aged <60 years?
Observational (n=340)
No
Does parasympathetic and sympathetic monitoring correlate with sudomotor testing in identifying early signs of autonomic neuropathy in patients aged <60 years?
Parasympathetic and sympathetic monitoring is highly concordant with sudomotor testing, offering a reliable non-invasive method to risk stratify patients for early autonomic neuropathy.
May support SweatC™ as alternative to P&S monitoring in patients <60; leaves open prospective validation against clinical outcomes.
The progression of autonomic dysfunction from peripheral autonomic neuropathy (PAN) to cardiovascular autonomic neuropathy, including diabetic autonomic neuropathy and advanced autonomic dysfunction, increases morbidity and mortality risks. PAN is the earliest stage of autonomic neuropathy. It typically involves small fiber disorder and often is an early component. Small fiber disorder (SFD) is an inflammation of the C-nerve fibers. Currently, the most universally utilized diagnostic test for SFD as an indicator of PAN is galvanic skin response (GSR), as it is less invasive than skin biopsy. It is important to correlate a patient's symptoms with several autonomic diagnostic tests so as not to treat patients with normal findings unnecessarily. At a large suburban northeastern United States (Sicklerville, NJ) autonomic clinic, 340 consecutive patients were tested with parasympathetic and sympathetic (P&S) monitoring (P&S Monitor 4.0; Physio PS, Inc., Atlanta, GA, USA) with cardiorespiratory analyses, and TMFlow (Omron Corp., Hoffman Estates, Chicago, IL, USA) with LD Technology sudomotor test (SweatC™). This is a prospective, nonrandomized, observational, population study. All patients were less than 60 y/o and were consecutively tested, analyzed and followed from February 2018 through May 2020. P&S Monitoring is based on cardiorespiratory analyses and SweatC™ sudomotor testing is based on GSR. Overall, regardless of the stage of autonomic neuropathy, SweatC™ and P&S Monitoring are in concordance for 306/340 (90.0%) of patients from this cohort. The result is an 89.4% negative predictive value of any P&S disorder if the sudomotor GSR test is negative and a positive predictive value of 90.4% if the sudomotor testing is positive. In detecting early stages of autonomic neuropathy, P&S Monitoring was equivalent to sudomotor testing with high sensitivity and specificity and high negative and positive predictive values. Therefore, either testing modality may be used to risk stratify patients with suspected autonomic dysfunction, including the earliest stages of PAN and SFD. Moreover, when these testing modalities were normal, their high negative predictive values aid in excluding an underlying autonomic nervous system dysfunction.
No takes yet. Share an insight, caveat, or question.
DePace et al. (2022) conducted an observational in Suspected autonomic dysfunction (n=340). Parasympathetic and sympathetic (P&S) monitoring vs. Sudomotor testing (SweatC™ / GSR) was evaluated on Concordance between P&S Monitoring and sudomotor testing. Parasympathetic and sympathetic monitoring showed 90.0% concordance with sudomotor testing for detecting autonomic neuropathy, with 90.4% positive and 89.4% negative predictive values.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: